Thiolated Chitosan Nanoparticles as a Delivery System for Antisense Therapy: Evaluation against EGFR in T47D Breast Cancer Cells [Retraction]

Abstract

Talaie F, Azizi E, Dinarvand R, Atyabi F. Int J Nanomedicine. 2011;6:1963‒1975. The Editor and Publisher of International Journal of Nanomedicine wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figures 3 and 7. Specifically, Figure 3A, chitosan nanoparticles, appears to have been duplicated with a similar image for Figure 3C, DOX-NAC-C nanoparticles. Figure 7B 1, FBS-free RPMI, appears to have been duplicated with a similar image for Figure 7B 7, NAP-C. Figure 7B 4, NAC-C, appears to have been duplicated with a similar image for Figure 7B 10, Chitosan. The authors responded to our queries but were unable to provide a satisfactory explanation for the duplicated images and the Editor requested for the article to be retracted. The authors were notified of this decision. Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Keywords

• thiolated chitosan
• nanoparticles
• doxorubicin
• antisense
• egfr
• t47d reast cancer cells
• controlled release